CytoDyn (CYDY)
OTHER OTC:CYDY

CytoDyn (CYDY) Stock Price & Analysis

591 Followers

CYDY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.15 - $1.26
Previous Close$0.26
Volume2.79M
Average Volume (3M)2.16M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$2.40M
Total Debt (Recent Filing)$37.28M
Price to Earnings (P/E)-1.0
Beta0.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-0.27
Shares Outstanding832,970,710
R-Squared0.00047
Standard Deviation0.49
10 Day Avg. Volume1,774,553
30 Day Avg. Volume2,157,018
Price to Book (P/B)-1.89
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusN/A
Alpha0.06
Number of Analyst Covering0


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CYDY FAQ

What was CytoDyn’s price range in the past 12 months?
CytoDyn lowest stock price was $0.15 and its highest was $1.26 in the past 12 months.
    What is CytoDyn’s market cap?
    Currently, no data Available
    When is CytoDyn’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were CytoDyn’s earnings last quarter?
    Currently, no data Available
    Is CytoDyn overvalued?
    According to Wall Street analysts CytoDyn’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does CytoDyn pay dividends?
      CytoDyn does not currently pay dividends.
      What is CytoDyn’s EPS estimate?
      CytoDyn’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does CytoDyn have?
      CytoDyn has 832,970,700 shares outstanding.
        What happened to CytoDyn’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of CytoDyn?
        Currently, no hedge funds are holding shares in CYDY

        ---

        CytoDyn Stock Smart Score

        5
        Neutral
        1
        2
        3
        4
        5
        6
        7
        8
        9
        10

        Technicals

        SMA
        Negative
        20 days / 200 days
        Momentum
        -54.43%
        12-Months-Change

        Fundamentals

        Return on Equity
        Trailing 12-Months
        Asset Growth
        -93.18%
        Trailing 12-Months
        The CytoDyn stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
        Learn more about TipRanks Smart Score

        Company Description

        CytoDyn

        CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, cancer, graft-versus-host disease (GVHD), and PCa test. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

        ---

        Forecast EPS vs Actual EPS

        Currently, no data available
        Please return soon. This page is being updated.

        Similar Stocks
        Company
        Price & Change
        Follow
        Heron Therapeutics
        Prelude Therapeutics
        Oyster Point Pharma
        Generation Bio
        Viking Therapeutics

        Popular Stocks

        ---
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis